Imprimis Pharmaceuticals (IMMY) Shares Sold by Granite Investment Partners LLC

Granite Investment Partners LLC cut its holdings in shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) by 63.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 67,355 shares of the specialty pharmaceutical company’s stock after selling 118,859 shares during the quarter. Granite Investment Partners LLC’s holdings in Imprimis Pharmaceuticals were worth $119,000 as of its most recent filing with the Securities and Exchange Commission.

Imprimis Pharmaceuticals opened at $2.25 on Friday, according to The company has a quick ratio of 1.14, a current ratio of 1.53 and a debt-to-equity ratio of 5.64.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter. Imprimis Pharmaceuticals had a negative return on equity of 248.39% and a negative net margin of 44.76%. The firm had revenue of $7.34 million for the quarter.

Separately, ValuEngine upgraded Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 18th.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

Want to see what other hedge funds are holding IMMY? Visit to get the latest 13F filings and insider trades for Imprimis Pharmaceuticals (NASDAQ:IMMY).

Institutional Ownership by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply